Stellar Biotechnologies Inc. (SBOTF)

[QualityStocks]

SBOT Presents Findings from Ongoing Research at Society for Glycobiology Meeting

Earlier today, Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX-V: KLH) announced the presentation of a preclinical poster relating to its ongoing research on Clostridium difficile. The poster, which was presented at the Society for Glycobiology 2015 Annual Meeting in San Francisco, California, reported data from the company’s studies into the potential development of C. difficile cell surface polysaccharide-KLH conjugate vaccines, or active immunotherapies, for the treatment of C. difficile infection.

Although C. difficile bacteria is normally present in the intestine, it sometimes overgrows as a result of antibiotic use. The infection that stems from this overgrowth has been linked to a host of dangerous side effects – including severe diarrhea and life-threatening intestinal conditions, such as colitis. Currently, the rate of U.S. cases of C. difficile overgrowth is at an all-time high. According to a 2011 study by the Centers for Disease Control and Prevention, C. difficile accounts for roughly 500,000 infections in the U.S. each year, costing patients and insurers approximately $4.8 billion in related medical expenses. Among those patients, an estimated 29,000 die within 30 days following initial diagnosis, further highlighting the importance of Stellar’s research program.

Stellar is the global leader in the sustainable manufacture of keyhole limpet hemocyanin (KLH) protein, which is an important immune-stimulating molecule widely used as an active pharmaceutical ingredient in immunotherapies. As a result of its proprietary method of sustainably producing GMP grade KLH, the company has partnered with a host of multinational pharmaceutical firms, renowned research centers and developers of active immunotherapies and therapeutic vaccines to address critically underserved indications in the biopharmaceutical industry.

Last month, the company successfully leveraged the marketability of its KLH protein by uplisting to the NASDAQ Capital Market. Following this move, Stellar reiterated intentions to expand its manufacturing capacity in order to better address the growing demand for KLH protein in immunotherapy. For prospective shareholders, the company’s recent progress represents an important step toward achieving sustainable corporate growth in the months to come.

To view the poster, Clostridium difficile Surface Polysaccharide-KLH Conjugate Vaccine Induced Th17-Featured Adaptive Immune Responses in Mice, visit http://content.equisolve.net/stellarbiotechnologies/media/0e37609debe1b998c4ccef5dd2a84a82.pdf

For more information, visit www.stellarbiotech.com